Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Actively Personalized Peptide Vaccinations Plus Immunomodulators in Patients With Newly Diagnosed Glioblastoma Concurrent to First Line Temozolomide Maintenance Therapy

NCT02149225 is registered in ClinicalTrials.gov with Immatics Biotechnologies GmbH as lead sponsor.

NCT NCT02149225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02149225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Actively Personalized Peptide Vaccinations Plus Immunomodulators in Patients With Newly Diagnosed Glioblastoma Concurrent to First Line Temozolomide Maintenance Therapy
Lead sponsor
Immatics Biotechnologies GmbH
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
June 30, 2018
Enrollment
16 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma